Ownership Capital B.V. Sells 48,961 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 3.3% in the 4th quarter, Holdings Channel reports. The firm owned 1,434,774 shares of the medical device company’s stock after selling 48,961 shares during the quarter. DexCom accounts for 4.0% of Ownership Capital B.V.’s holdings, making the stock its 13th largest position. Ownership Capital B.V.’s holdings in DexCom were worth $178,041,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Sands Capital Management LLC raised its position in shares of DexCom by 4.3% during the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after buying an additional 557,543 shares in the last quarter. Blair William & Co. IL raised its position in shares of DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after buying an additional 73,654 shares in the last quarter. Northern Trust Corp raised its position in shares of DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after buying an additional 91,249 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of DexCom by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock valued at $201,618,000 after buying an additional 28,621 shares in the last quarter. Finally, Winslow Capital Management LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at $173,120,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,375 shares of company stock valued at $25,530,859. Corporate insiders own 0.41% of the company’s stock.

DexCom Trading Down 9.9 %

DexCom stock traded down $13.67 during trading hours on Friday, reaching $124.34. The stock had a trading volume of 8,578,184 shares, compared to its average volume of 2,409,208. The company has a fifty day simple moving average of $131.13 and a 200-day simple moving average of $118.30. The stock has a market cap of $49.24 billion, a PE ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. Analysts forecast that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of analyst reports. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Raymond James lifted their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.